| Type | Sym | Class | Transaction | Value $ | Shares | Change % | * Price $ | Shares After | Date | Ownership | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|
| transaction | IMRX | Class A Common Stock | Award | $7.04K | +4.34K | +178.47% | $1.62 | 6.78K | Mar 15, 2024 | Direct | F1, F2, F3 |
| transaction | IMRX | Class A Common Stock | Purchase | $3.01K | +1.11K | +16.33% | $2.72 | 7.89K | Mar 21, 2024 | Direct | F4 |
| transaction | IMRX | Class A Common Stock | Purchase | $1K | +393 | +4.98% | $2.55 | 8.28K | Mar 22, 2024 | Direct |
| Id | Content |
|---|---|
| F1 | The reporting person is voluntarily reporting the acquisition of shares of the issuer's Class A Common Stock pursuant to the Immuneering Corporation 2021 Employee Stock Purchase Plan (the "ESPP"), for the ESPP purchase period of September 15, 2023 through March 15, 2024. This transaction is also exempt pursuant to Rule 16b-3(c) promulgated pursuant to the Securities Exchange Act of 1934. |
| F2 | The relevant Offering Period (as defined in the ESPP) ended, and the shares were acquired, on the Purchase Date (as defined in the ESPP) of March 15, 2024. |
| F3 | In accordance with the ESPP, the shares were purchased at a price not less than eighty-five percent (85%) of the Fair Market Value (as defined in the ESPP) of a share of Class A Common Stock on the Purchase Date of March 15, 2024. |
| F4 | This transaction was executed in multiple trades through a broker-dealer at prices ranging from $2.675 to $2.74. The price reported in this column reflects the weighted average purchase price. Upon request, the reporting person will provide to the SEC staff full information regarding the number of shares acquired at each price. |